As chlamydia and gonorrhea continue to be a menace to society, but especially women, Earth Science Tech, Inc. (OTC:ETST) has buckled down on improving testing for these infections. They recently announced a partnership with a private laboratory, BNK Canada, Inc., to develop new testing capabilities for the company’s flagship medical device, the MSN-2 machine.

To date, the company has completely built the capability for the machine to test for chlamydia. In partnership with BNK, Earth Science Tech intends to expand the capabilities to include testing for gonorrhea, trichomoniasis, and a complete body fluid panel to test for different types of HPV. These tests will open new markets for the company, and allow them to better serve women, who are at a higher risk for developing cancer because of many STIs.

BNK is a seasoned research and development company based in Canada, and Earth Science Tech intends to leverage their expertise to cut their research and development costs, in addition to trimming the amount of time it takes to bring new solutions from concept to market.

In closing, the company’s CEO mentioned that current WHO (World Health Organization) guidelines recommend that all pregnant women be screened for chlamydia prior to giving birth, as the infection can be spread to children and cause pneumonia and/or conjunctivitis, which can lead to permanent blindness in a newborn. As awareness spreads, this testing will become more important, and the market is expected to grow, a development which could directly benefit Earth Science Tech within their current (and future) testing capabilities.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: